News

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...
IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for ...
“Sexuality and intimacy are important aspects of quality of life and may also reduce some of the psychosocial distress ...
Gepotidacin was approved by the FDA earlier this year, under the Blujepa brand, as the first oral antibiotic to offer a new ...
One near-term rival is Johnson & Johnson's FcRn inhibitor nipocalimab, which started a phase 3 programme last December.
Haematological cancers are a recognised potential side effect with Skysona and were already mentioned in a boxed warning on ...
One major and often overlooked factor contributing to this imbalance is the way health outcomes are measured in clinical ...
Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...
The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who ...
More details have emerged of a UK plan for new medicines to get simultaneous decisions from the MHRA and NICE on their use by the NHS.
Jazz has reached an agreement to buy Chimerix for around $935 million, adding a brain cancer drug heading for an FDA approval decision in August.
There is currently no approved treatment for intracerebral haemorrhagic stroke, but Belgian start-up Bioxodes hopes to change that.